Handel Hikma Pharmaceuticals PLC - HIK CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.07 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.021808% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | -0.00011% | ||||||||
Gebyr natten over, tid | 21:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | GBP | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United Kingdom of Great Britain and Northern Ireland | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Hikma Pharmaceuticals PLC ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Tidligere luk* | 16.59 |
Åben* | 16.55 |
1-Års Ændring* | -18.91% |
Dagens Spænd* | 16.55 - 16.97 |
52-Ugers Spænd | 11.75-21.37 |
Gennemsnitlig Volumen (10 dage) | 461.89K |
Gennemsnitlig Volumen (3 måneder) | 9.16M |
Market Cap | 3.65B |
P/E-forhold | 24.64 |
Udestående aktier | 220.26M |
Omsætning | 2.05B |
EPS | 0.67 |
Dividend (Udbytte %) | 2.86964 |
Beta | 0.35 |
Næste indtjeningsopgørelse | Aug 3, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Mar 20, 2023 | 16.59 | 0.11 | 0.67% | 16.48 | 16.71 | 16.29 |
Mar 17, 2023 | 16.59 | -0.83 | -4.76% | 17.42 | 17.48 | 16.53 |
Mar 16, 2023 | 17.42 | 0.14 | 0.81% | 17.28 | 17.56 | 17.19 |
Mar 15, 2023 | 17.28 | -0.14 | -0.80% | 17.42 | 17.50 | 17.18 |
Mar 14, 2023 | 17.39 | 0.16 | 0.93% | 17.23 | 17.42 | 16.98 |
Mar 13, 2023 | 17.21 | -0.40 | -2.27% | 17.61 | 17.68 | 17.13 |
Mar 10, 2023 | 17.56 | 0.00 | 0.00% | 17.56 | 17.85 | 17.49 |
Mar 9, 2023 | 17.87 | 0.03 | 0.17% | 17.84 | 17.95 | 17.73 |
Mar 8, 2023 | 17.84 | 0.04 | 0.22% | 17.80 | 18.13 | 17.78 |
Mar 7, 2023 | 18.10 | 0.31 | 1.74% | 17.79 | 18.46 | 17.61 |
Mar 6, 2023 | 17.79 | 0.35 | 2.01% | 17.44 | 17.93 | 17.44 |
Mar 3, 2023 | 17.53 | 0.12 | 0.69% | 17.41 | 17.72 | 17.41 |
Mar 2, 2023 | 17.56 | 0.37 | 2.15% | 17.19 | 17.68 | 17.19 |
Mar 1, 2023 | 17.38 | 0.11 | 0.64% | 17.27 | 17.59 | 17.24 |
Feb 28, 2023 | 17.27 | -0.11 | -0.63% | 17.38 | 17.38 | 17.10 |
Feb 27, 2023 | 17.37 | 0.28 | 1.64% | 17.09 | 17.53 | 17.07 |
Feb 24, 2023 | 17.15 | 0.01 | 0.06% | 17.14 | 17.43 | 16.68 |
Feb 23, 2023 | 17.14 | -0.43 | -2.45% | 17.57 | 18.56 | 16.72 |
Feb 22, 2023 | 17.56 | -0.20 | -1.13% | 17.76 | 17.80 | 17.55 |
Feb 21, 2023 | 17.75 | 0.25 | 1.43% | 17.50 | 18.06 | 17.50 |
Hikma Pharmaceuticals PLC Events
Tid (UTC) (UTC) | Land | Begivenhed |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total omsætning | 2553 | 2341 | 2203 | 2076 | 1936 |
Omsætning | 2553 | 2341 | 2203 | 2076 | 1936 |
Kost af omsætning, Total | 1252 | 1128 | 1108 | 1004 | 963 |
Bruttofortjeneste | 1301 | 1213 | 1095 | 1072 | 973 |
Totale Driftsudgifter | 1955 | 1739 | 1669 | 1731 | 2709 |
Salgs/Generelle/Admin. Udgifter, Total | 488 | 464 | 453 | 437 | 426 |
Forskning & Udvikling | 143 | 137 | 126 | 118 | 115 |
Usædvanlig Udgift (Indkomst) | -39 | -76 | -60 | 104 | 1159 |
Other Operating Expenses, Total | 38 | 44 | 8 | 68 | 46 |
Driftsindtægter | 598 | 602 | 534 | 345 | -773 |
Renteindkomst (Udgift), Netto Ikke-Drift | -41 | -33 | -27 | -39 | 43 |
Andre, Netto | -13 | -11 | -16 | -13 | -8 |
Netto Indkomst Før Skat | 544 | 558 | 491 | 293 | -738 |
Netto Indkomst Efter Skat | 420 | 430 | 487 | 285 | -888 |
Minoritetsrente | 1 | 1 | -1 | -3 | -4 |
Netto Indkomst Før Ekstra Ting | 421 | 431 | 486 | 282 | -892 |
Netto Indkomst | 421 | 431 | 486 | 282 | -843 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 421 | 431 | 486 | 282 | -892 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 421 | 431 | 486 | 282 | -843 |
Fortyndelsesændring | 0 | ||||
Fortyndet Netto Indkomst | 421 | 431 | 486 | 282 | -843 |
Fortyndet Vægtet Gennemsnit Aktier | 233 | 238 | 243 | 242 | 240 |
Fortyndet EPS Uden Ekstraordinære Ting | 1.80687 | 1.81092 | 2 | 1.16529 | -3.71667 |
Dividends per Share - Common Stock Primary Issue | 0.55055 | 0.50649 | 0.4714 | 0.37647 | 0.34471 |
Fortyndet Normaliseret EPS | 1.66094 | 1.4958 | 2.16049 | 1.90496 | 0.99167 |
Totale Ekstraordinære Ting | 0 | 49 | |||
Depreciation / Amortization | 73 | 42 | 34 |
Dec 2021 | Jun 2021 | Dec 2020 | Jun 2020 | Dec 2019 | |
---|---|---|---|---|---|
Total omsætning | 1337 | 1216 | 1209 | 1132 | 1160 |
Omsætning | 1337 | 1216 | 1209 | 1132 | 1160 |
Kost af omsætning, Total | 652 | 600 | 598 | 530 | 609 |
Bruttofortjeneste | 685 | 616 | 611 | 602 | 551 |
Totale Driftsudgifter | 1082 | 873 | 900 | 839 | 873 |
Salgs/Generelle/Admin. Udgifter, Total | 256 | 232 | 235 | 229 | 237 |
Forskning & Udvikling | 84 | 59 | 75 | 62 | 68 |
Depreciation / Amortization | 44 | 29 | 21 | 21 | 17 |
Usædvanlig Udgift (Indkomst) | 24 | -63 | -44 | -32 | -42 |
Other Operating Expenses, Total | 22 | 16 | 15 | 29 | -16 |
Driftsindtægter | 255 | 343 | 309 | 293 | 287 |
Renteindkomst (Udgift), Netto Ikke-Drift | -30 | -24 | -25 | -19 | -22 |
Netto Indkomst Før Skat | 225 | 319 | 284 | 274 | 265 |
Netto Indkomst Efter Skat | 172 | 248 | 218 | 212 | 302 |
Minoritetsrente | 1 | 0 | 1 | 0 | -1 |
Netto Indkomst Før Ekstra Ting | 173 | 248 | 219 | 212 | 301 |
Netto Indkomst | 173 | 248 | 219 | 212 | 301 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 173 | 248 | 219 | 212 | 301 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 173 | 248 | 219 | 212 | 301 |
Fortyndet Netto Indkomst | 173 | 248 | 219 | 212 | 301 |
Fortyndet Vægtet Gennemsnit Aktier | 234 | 232 | 232.881 | 243.119 | 242.899 |
Fortyndet EPS Uden Ekstraordinære Ting | 0.73932 | 1.06897 | 0.9404 | 0.872 | 1.2392 |
Dividends per Share - Common Stock Primary Issue | 0.37405 | 0.18 | 0.33778 | 0.16 | 0.3211 |
Fortyndet Normaliseret EPS | 0.90171 | 0.75862 | 0.76005 | 0.73626 | 1.44093 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 2094 | 1922 | 1848 | 1668 | 1574 |
Likvider og Kortsigtede Investeringer | 450 | 347 | 465 | 276 | 227 |
Cash | 155 | 85 | 94 | 112 | 98 |
Likvider & Lignende | 22 | 35 | 39 | 36 | 49 |
Kortsigtede Investeringer | 273 | 227 | 332 | 128 | 80 |
Totale Tilgodehavender, Netto | 876 | 734 | 749 | 748 | 719 |
Accounts Receivable - Trade, Net | 781 | 662 | 637 | 654 | 650 |
Total Inventory | 695 | 757 | 568 | 528 | 488 |
Prepaid Expenses | 65 | 58 | 49 | 57 | 41 |
Other Current Assets, Total | 8 | 26 | 17 | 59 | 99 |
Total Assets | 4372 | 4135 | 3930 | 3497 | 3388 |
Property/Plant/Equipment, Total - Net | 1146 | 1068 | 962 | 870 | 828 |
Property/Plant/Equipment, Total - Gross | 1955 | 1841 | 1690 | 1549 | 1489 |
Accumulated Depreciation, Total | -809 | -773 | -728 | -679 | -661 |
Goodwill, Net | 285 | 289 | 282 | 279 | 282 |
Intangibles, Net | 607 | 587 | 552 | 487 | 503 |
Long Term Investments | 46 | 34 | 29 | 38 | 26 |
Other Long Term Assets, Total | 194 | 235 | 257 | 155 | 175 |
Total Current Liabilities | 1016 | 1028 | 1471 | 893 | 797 |
Accounts Payable | 262 | 279 | 286 | 263 | 218 |
Accrued Expenses | 194 | 175 | 173 | 185 | 134 |
Notes Payable/Short Term Debt | 64 | 117 | 60 | 65 | 59 |
Current Port. of LT Debt/Capital Leases | 57 | 51 | 518 | 10 | 28 |
Other Current Liabilities, Total | 439 | 406 | 434 | 370 | 358 |
Total Liabilities | 1919 | 2000 | 1813 | 1812 | 1874 |
Total Long Term Debt | 725 | 764 | 107 | 562 | 690 |
Long Term Debt | 651 | 692 | 48 | 539 | 670 |
Capital Lease Obligations | 74 | 72 | 59 | 23 | 20 |
Deferred Income Tax | 24 | 31 | 20 | 16 | 49 |
Minority Interest | 14 | 13 | 12 | 12 | 14 |
Other Liabilities, Total | 140 | 164 | 203 | 329 | 324 |
Total Equity | 2453 | 2135 | 2117 | 1685 | 1514 |
Common Stock | 42 | 41 | 41 | 40 | 40 |
Additional Paid-In Capital | 282 | 282 | 282 | 282 | 282 |
Retained Earnings (Accumulated Deficit) | 2353 | 2011 | 2030 | 1618 | 1420 |
Treasury Stock - Common | 0 | -1 | -1 | -1 | |
Other Equity, Total | -224 | -199 | -235 | -254 | -227 |
Total Liabilities & Shareholders’ Equity | 4372 | 4135 | 3930 | 3497 | 3388 |
Total Common Shares Outstanding | 231.498 | 230.458 | 242.319 | 241.455 | 240.679 |
Dec 2021 | Jun 2021 | Dec 2020 | Jun 2020 | Dec 2019 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 2094 | 1955 | 1922 | 1878 | 1848 |
Likvider og Kortsigtede Investeringer | 450 | 346 | 347 | 436 | 465 |
Likvider & Lignende | 22 | 2 | 323 | 413 | 442 |
Kortsigtede Investeringer | 273 | 101 | 24 | 23 | 23 |
Totale Tilgodehavender, Netto | 811 | 780 | 734 | 671 | 749 |
Accounts Receivable - Trade, Net | 719 | 693 | 662 | 560 | 637 |
Total Inventory | 695 | 736 | 757 | 684 | 568 |
Prepaid Expenses | 65 | 78 | 58 | 66 | 49 |
Other Current Assets, Total | 73 | 15 | 26 | 21 | 17 |
Total Assets | 4372 | 4180 | 4135 | 3970 | 3930 |
Property/Plant/Equipment, Total - Net | 1146 | 1061 | 1068 | 970 | 962 |
Goodwill, Net | 285 | 286 | 289 | 280 | 282 |
Intangibles, Net | 607 | 620 | 587 | 570 | 552 |
Long Term Investments | 46 | 36 | 34 | 32 | 29 |
Other Long Term Assets, Total | 194 | 222 | 235 | 240 | 257 |
Total Current Liabilities | 1016 | 960 | 1028 | 1070 | 1471 |
Accounts Payable | 262 | 226 | 279 | 272 | 286 |
Accrued Expenses | 194 | 145 | 175 | 141 | 173 |
Notes Payable/Short Term Debt | 64 | 132 | 117 | 108 | 60 |
Current Port. of LT Debt/Capital Leases | 57 | 49 | 51 | 30 | 518 |
Other Current Liabilities, Total | 439 | 408 | 406 | 519 | 434 |
Total Liabilities | 1919 | 1890 | 2000 | 2080 | 1813 |
Total Long Term Debt | 725 | 751 | 764 | 789 | 107 |
Long Term Debt | 651 | 676 | 692 | 730 | 48 |
Capital Lease Obligations | 74 | 75 | 72 | 59 | 59 |
Deferred Income Tax | 24 | 21 | 31 | 22 | 20 |
Minority Interest | 14 | 13 | 13 | 10 | 12 |
Other Liabilities, Total | 140 | 145 | 164 | 189 | 203 |
Total Equity | 2453 | 2290 | 2135 | 1890 | 2117 |
Common Stock | 42 | 41 | 41 | 41 | 41 |
Additional Paid-In Capital | 282 | 282 | 282 | 282 | 282 |
Retained Earnings (Accumulated Deficit) | 2353 | 2197 | 2011 | 1814 | 2030 |
Treasury Stock - Common | 0 | 0 | 0 | -1 | |
Other Equity, Total | -224 | -230 | -199 | -247 | -235 |
Total Liabilities & Shareholders’ Equity | 4372 | 4180 | 4135 | 3970 | 3930 |
Total Common Shares Outstanding | 231.498 | 231.432 | 230.458 | 230.411 | 242.319 |
Cash | 155 | 243 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netto indkomst/Startlinje | 544 | 558 | 491 | 293 | -738 |
Likvider Fra Driftsaktiviteter | 638 | 464 | 472 | 430 | 443 |
Likvider Fra Driftsaktiviteter | 145 | 91 | 73 | 69 | 77 |
Amortization | 26 | 40 | 59 | ||
Ikke-Likvide Ting | 108 | 84 | 34 | 116 | 1116 |
Cash Taxes Paid | 129 | 61 | 108 | 63 | 103 |
Likvid Rente Betalt | 50 | 39 | 44 | 51 | 57 |
Ændringer i Driftskapital | -159 | -269 | -152 | -88 | -71 |
Likvider fra Investeringsaktiviteter | -238 | -283 | -151 | -96 | -151 |
Kapitaludgifter | -229 | -224 | -186 | -139 | -151 |
Andre Investerings-Cash-Flow-Ting, Total | -9 | -59 | 35 | 43 | 0 |
Likvider fra Financieringsaktiviteter | -287 | -298 | -155 | -278 | -220 |
Financiering af Cash-Flow-Ting | -53 | -34 | -48 | -53 | -63 |
Total Cash Dividends Paid | -120 | -109 | -97 | -84 | -79 |
Udstedelse (Pensionering) af Aktier, Netto | 0 | -375 | |||
Udstedelse (Pensionering) af Gæld, Netto | -114 | 220 | -10 | -141 | -78 |
Udenlandsk Børs Effekter | -10 | -2 | 0 | -7 | 0 |
Netto Ændring i Likviditet | 103 | -119 | 166 | 49 | 72 |
Dec 2021 | Jun 2021 | Dec 2020 | Jun 2020 | Dec 2019 | |
---|---|---|---|---|---|
Net income/Starting Line | 544 | 319 | 558 | 274 | 491 |
Cash From Operating Activities | 638 | 224 | 464 | 292 | 472 |
Cash From Operating Activities | 145 | 44 | 91 | 38 | 73 |
Amortization | 26 | ||||
Non-Cash Items | 108 | 28 | 84 | 34 | 34 |
Cash Taxes Paid | 129 | 88 | 61 | 19 | 108 |
Cash Interest Paid | 50 | 25 | 39 | 24 | 44 |
Changes in Working Capital | -159 | -167 | -269 | -54 | -152 |
Cash From Investing Activities | -238 | -104 | -283 | -100 | -151 |
Capital Expenditures | -229 | -94 | -224 | -101 | -186 |
Other Investing Cash Flow Items, Total | -9 | -10 | -59 | 1 | 35 |
Cash From Financing Activities | -287 | -112 | -298 | -220 | -155 |
Financing Cash Flow Items | -53 | -26 | -34 | -17 | -48 |
Total Cash Dividends Paid | -120 | -78 | -109 | -73 | -97 |
Issuance (Retirement) of Debt, Net | -114 | -8 | 220 | 241 | -10 |
Foreign Exchange Effects | -10 | -9 | -2 | -1 | 0 |
Net Change in Cash | 103 | -1 | -119 | -29 | 166 |
Issuance (Retirement) of Stock, Net | 0 | 0 | -375 | -371 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
Darhold Ltd | Corporation | 27.2402 | 60000000 | 0 | 2022-02-23 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.4336 | 11968104 | -266262 | 2023-02-15 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 5.2469 | 11556882 | 0 | 2022-02-23 | LOW |
Capital Research Global Investors | Investment Advisor | 5.1691 | 11385712 | 0 | 2022-02-23 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.9935 | 4390912 | 1080315 | 2022-12-12 | LOW |
Schroder Investment Management Ltd. (SIM) | Investment Advisor/Hedge Fund | 1.8402 | 4053212 | -29858 | 2023-02-01 | LOW |
Epoch Investment Partners, Inc. | Investment Advisor | 0.9948 | 2191152 | 716350 | 2022-12-01 | LOW |
California State Teachers Retirement System | Pension Fund | 0.9854 | 2170477 | 197506 | 2022-06-30 | LOW |
Baillie Gifford & Co. | Investment Advisor | 0.9087 | 2001573 | 62506 | 2022-12-12 | LOW |
Templeton Investment Counsel, L.L.C. | Investment Advisor/Hedge Fund | 0.8399 | 1850000 | 1850000 | 2022-06-06 | LOW |
Aegon Asset Management Ltd | Investment Advisor | 0.8313 | 1830945 | 0 | 2023-02-01 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.5902 | 1299980 | 136377 | 2023-02-01 | LOW |
Newton Investment Management Ltd. | Investment Advisor | 0.5736 | 1263337 | 39736 | 2023-01-31 | LOW |
GAM International Management Ltd. | Investment Advisor/Hedge Fund | 0.504 | 1110079 | 217500 | 2022-12-12 | MED |
Premier Asset Management Ltd | Investment Advisor/Hedge Fund | 0.4811 | 1059584 | 106061 | 2022-11-30 | LOW |
State Street Global Advisors (UK) Ltd. | Investment Advisor/Hedge Fund | 0.4627 | 1019052 | 0 | 2023-02-01 | LOW |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 0.4468 | 984025 | -19804 | 2022-12-12 | LOW |
Fidelity Investments Canada ULC | Investment Advisor | 0.4424 | 974429 | 974429 | 2022-12-01 | LOW |
Fidelity International | Investment Advisor | 0.3986 | 877896 | 0 | 2023-02-01 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.3542 | 780259 | -3067183 | 2023-02-01 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Hikma Company profile
Om Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals Plc er en lægemiddelvirksomhed. Virksomheden fokuserer på udvikling, fremstilling, markedsføring og salg af en bred vifte af generiske lægemidler, mærkevarer og farmaceutiske produkter i faste, halvfaste, flydende og injicerbare endelige doseringsformer. Selskabet opererer gennem tre segmenter, såsom injektionspræparater, generiske lægemidler og mærkevarer. Forretningen Injectables udvikler og fremstiller generiske injicerbare produkter, som primært anvendes på hospitaler. Virksomheden generiske produkter udvikler og fremstiller orale og andre generiske produkter, der ikke kan injiceres. Branded-virksomheden udvikler og fremstiller generiske mærkevarer og markedsfører og sælger patenterede produkter i licens i Mellemøsten og Nordafrika (MENA). Selskabets produkter sælges i detailhandelen og på hospitalsmarkederne. Virksomheden markedsfører også sine produkter i Canada, som omfatter ca. 25 sterile injicerbare produkter, tre øjenlægeprodukter under licens og en pipeline med yderligere syv produkter.
Industry: | Pharmaceuticals (NEC) |
1 New Burlington Place
LONDON
W1S 2HR
GB
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com